The European Commission has granted approval for Amgen’s BLINCYTO® (blinatumomab) for the treatment of pediatric patients with certain forms of B cell…
Drug developer Berlin Cures announced the successful completion of its Phase 1 study of its lead candidate BC 007 for the treatment of cardiomyopathy.…